Apyx Medical Corp (APYX) - 10-K Summary for Fiscal Year Ended December 31, 2025
Business Context and Reporting Period
Apyx Medical Corporation is a surgical aesthetics company focused on the cosmetic surgery market. Its primary products include the Renuvion and J-Plasma Helium Plasma Platform Technology and the newly launched AYON Body Contouring System. The company operates two segments: Surgical Aesthetics (85.8% of revenue) and OEM (14.2% of revenue). This filing covers the fiscal year ended December 31, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $52.8 million | $48.1 million |
| Gross Profit | $33.0 million | $29.4 million |
| Gross Margin | 62.5% | 61.0% |
| Operating Loss | ($6.4) million | ($18.8) million |
| Net Loss | ($11.1) million | ($23.6) million |
| Cash Used in Operations | ($8.0) million | ($18.0) million |
| Cash and Equivalents (Year End) | $31.7 million | $31.7 million |
| Long-Term Debt (Net) | $34.8 million | $33.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 9.9% year-over-year, driven by a 17.4% increase in the Surgical Aesthetics segment following the commercial launch of the AYON system in September 2025. The OEM segment declined 20.9% due to reduced sales volume to existing customers.
- Cost Reductions: Operating expenses decreased significantly to under $40.0 million in 2025 (down from $48.2 million in 2024). This was achieved through a 25% reduction in the U.S. workforce in late 2024, elimination of bonuses in 2024, and reduced professional fees and R&D spending.
- Profitability Improvement: The operating loss narrowed by approximately $12.4 million compared to 2024, reflecting both revenue growth and aggressive cost-cutting measures.
- Capital Raises: The company raised approximately $9.1 million in net proceeds from a public offering in November 2025 and $7.0 million from a registered direct offering in November 2024.
Guidance, Outlook, and Risks
- Product Outlook: Management anticipates receiving FDA clearance for the AYON power liposuction label expansion in Q2 2026. The company expects the Surgical Aesthetics segment to continue growing, potentially benefiting from loose skin issues caused by GLP-1 weight-loss drugs.
- Liquidity: The company maintains $31.7 million in cash. While losses are expected to continue in the near term, management plans to fund operations through existing cash, product sales, and potential additional financing. A shelf registration statement for up to $100 million in securities was filed in December 2025.
- Debt Covenants: The company is currently in compliance with its Perceptive Credit Agreement. Key covenants include meeting trailing twelve-month revenue targets for the Surgical Aesthetics segment ($37.0M for 2025, $52.4M for 2026) and maintaining operating expenses below $40.0 million in 2025 and $45.0 million in 2026.
- Risks: Significant risks include the impact of GLP-1 drugs on elective surgery demand, supply chain disruptions, potential litigation regarding product liability (with estimated losses accrued), and the need for future capital raises which may result in dilution.
Investor Verification Checklist
- Covenant Compliance: Verify that the company continues to meet the specific revenue and operating expense covenants of the Perceptive Credit Agreement to avoid default.
- AYON Adoption: Monitor the commercial uptake of the AYON system and the timeline for the anticipated Q2 2026 FDA clearance for power liposuction.
- Litigation Exposure: Review Note 17 regarding product liability claims; verify if insurance coverage remains sufficient given the accrued deductibles and potential for losses exceeding policy limits.
- Cash Burn Rate: Assess the sustainability of the current cash position ($31.7M) against the recurring operating losses and the timeline for achieving profitability.
- GLP-1 Impact: Evaluate the actual market impact of GLP-1 medications on the volume of cosmetic procedures and whether the anticipated "tailwind" for skin tightening procedures materializes.